Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

C -R Pradeep^{1

2}, A Zeisel³, W J Köstler^{1

4}, M Lauriola¹, J Jacob-Hirsch⁵, B Haibe-Kains^{6

7}, N Amariglio⁵, N Ben-Chetrit¹, A Emde¹, I Solomonov⁸, G Neufeld⁹, M Piccart⁶, I Sagi⁸, C Sotiriou⁶, G Rechavi⁵, E Domany³, C Desmedt⁶, Y Yarden¹⁰

Affiliations

¹ Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
² Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
³ Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
⁴ Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁵ Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁶ Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.
⁷ Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium.
⁸ Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
⁹ Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
¹⁰ Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.

Published Erratum

C -R Pradeep et al. Oncogene. 2025 May.

. 2025 May;44(17):1207.

doi: 10.1038/s41388-025-03362-8.

¹ Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
² Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
³ Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
⁴ Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁵ Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁶ Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.
⁷ Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium.
⁸ Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
⁹ Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
¹⁰ Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.

No abstract available

Erratum for

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y. Pradeep CR, et al. Oncogene. 2012 Aug 2;31(31):3569-83. doi: 10.1038/onc.2011.547. Epub 2011 Dec 5. Oncogene. 2012. PMID: 22139081 Free PMC article.